title: [The treatment of binge eating disorder - a review].
abstract: The binge eating disorder is a relatively new type of eating disorders, which was first described in 1992, and became a distinct nosological entity in the system of DSM-5 in 2013. Its central symptom is the binge, which is not followed by compensatory behaviours as in bulimia nervosa. Therefore, the patients are generally obese. The prevalence of the disorder is 1-3% in the general population, but much higher in help-seeking obese subjects. The two main goals of the therapy is body weight reduction, and the cessation of binges. In the pharmacotherapy of binge eating disorder the antidepressants are recommended mainly in the case of unsuccessful psychotherapy, and in treating comorbid depression. In the field of psychotherapy data are available mainly on the effectiveness of cognitive behavioural therapy, dialectic behaviour therapy, behavioural weight loss, and interpersonal therapy. Effectivity studies on new therapeutic methods and treatment combinations are needed as well as long term follow-up studies.
authors.affiliation: Orszagos Egeszsegfejlesztesi Intezet, Budapest, Hungary, E-mail: tury@t-online.hu.
authors.forename: Ildikó
authors.initials: I
authors.lastname: Papp
authors.forename: Irena
authors.initials: I
authors.lastname: Szumska
authors.forename: Ferenc
authors.initials: F
authors.lastname: Túry
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D056912:Binge-Eating Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D002032:Bulimia / Q000175:diagnosis / Q000628:therapy; D015928:Cognitive Behavioral Therapy; D039721:Diagnostic and Statistical Manual of Mental Disorders; D037001:Directive Counseling; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D020407:Internet; D015201:Meta-Analysis as Topic; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D012657:Self-Help Groups; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012720:Severity of Illness Index; D000077236:Topiramate; D015430:Weight Gain; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D000928:Antidepressive Agents; D005632:Fructose; D017367:Selective Serotonin Reuptake Inhibitors; D000077236:Topiramate